drugset
drugset / Trial / NCT05469360

Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants

NCT05469360 ↗

Phase 1 Active not recruiting 38 enrolled Novartis Pharmaceuticals
RandomizedSequentialDouble-blindTreatment

Summary

Phase 1b study to assess the pharmacodynamics, safety, tolerability, and pharmacokinetics of NIO752 in patients with early Alzheimer's disease (AD)

Timeline

Start
2023-02-23
Primary completion
2026-07-30
Completion
2027-09-24

Drugs

EvaluationDrugModalityDoseRoute
Subject NIO752 Antisense oligonucleotide — Intrathecal

Indications

Alzheimer disease cognitive impairment with or without cerebellar ataxia